Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

July 25, 2015

La Jolla, CA

Continuing Education


Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend

This educational activity is specifically designed for medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, and other physicians, clinicians, physicians-in-training, and healthcare professionals (nurses, pharmacists, physician assistants, etc.) involved and interested in the therapeutic management of patients with lung and other thoracic cancers.


Objectives


Upon completion of this educational activity, participants should be able to:

  • Examine the potential of molecular profiling to detect all types of mutations in lung cancer
  • Identify optimal treatment strategies for small cell lung cancer and oligo-metastatic NSCLC
  • Examine the rationale for novel, next generation clinical trials in lung cancer
  • Evaluate emerging options in radiotherapy and systemic therapy for patients with advanced lung cancer
  • Assess promising adjuvant treatment options for patients with mutant and undetectable mutant NSCLC
  • Select individualized targeted therapies for NSCLC patients with EGFR, ALK, or other mutations
  • Interpret the latest data and challenges from ongoing clinical trials focused on immunotherapy for NSCLC